Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086677 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
A Phase 1 study of Streptococcus Pneumoniae, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 372
- Enrollment target
- 5
- Study locations
NCT07086677 is a Phase 1 study of Streptococcus Pneumoniae that is actively recruiting participants, run by Pfizer. The registered enrollment target is 372 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT07086677, a Phase 1 study of Streptococcus Pneumoniae, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 372 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.
Conditions Studied
Interventions
- BIOLOGICAL PG4 vaccine in Buffer 1 with low dose PA-001
- BIOLOGICAL PG4 in Buffer 1 with low dose PA-002
- BIOLOGICAL PG4 in Buffer 1 with high dose PA-001
- BIOLOGICAL PG4 vaccine in Buffer 1 with high dose PA-002
- BIOLOGICAL PG4 vaccine in Buffer 2
Study Locations (5)
California
- Orange County Research Center - Lake Forest
Florida
- Indago Research & Health Center, Inc - Hialeah
Kansas
- Johnson County Clinical Trials - Lenexa
Nebraska
- Velocity Clinical Research, Omaha - Omaha
Ohio
- CTI Clinical Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2027-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086677
The ClinicalTrials.gov registry entry for NCT07086677 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Streptococcus Pneumoniae appearing as the primary indexed condition, and to 5 interventions - of which PG4 vaccine in Buffer 1 with low dose PA-001 is the first listed.
NCT07086677 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT07086677 about?
NCT07086677 is a clinical study titled "A Study to Learn About How a New Pneumococcal Vaccine Works in Adults". The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but l...
What is the current status of trial NCT07086677?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 372 participants. The study started on 2025-07-22. Estimated completion is 2027-09-23.
What conditions does trial NCT07086677 study?
This clinical trial studies the following conditions: Streptococcus Pneumoniae.
What interventions are being tested in trial NCT07086677?
The interventions under investigation include: PG4 vaccine in Buffer 1 with low dose PA-001 (BIOLOGICAL), PG4 in Buffer 1 with low dose PA-002 (BIOLOGICAL), PG4 in Buffer 1 with high dose PA-001 (BIOLOGICAL), PG4 vaccine in Buffer 1 with high dose PA-002 (BIOLOGICAL), PG4 vaccine in Buffer 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07086677?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07086677 being conducted?
This trial has 5 study locations across California, Florida, Kansas, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Streptococcus Pneumoniae
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.